RapidArc vs. IMRT Planning: A Comparative Study with Dosimetric Validation for Head and Neck, Glioma and Pancreas Cancer

Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy

“…Sensitivity of the RapidArc technique to tighter thresholds was investigated and proved to be highly satisfactory with both the GLAaS and PTW-729 methods. The quality of GLAaS based measurement for RapidArc is confirmed in other studies with different detectors [ 10 , 34 ] where either gafchromic films or other 2D systems were used and GAI or equivalent metrics exceeded 95% as well. This consistency suggests also the limited relevance of the fact that with GLAaS dosimetry the EPID detector rotates together with the gantry although it would not allow detecting potential mismatches between planned and actual positions.…”

Is RapidArc more susceptible to delivery uncertainties than dynamic IMRT?

“…5 and 6) have been implemented clinically, investigators have steadily reported plan and dosimetric comparisons for several tumor sites as compared to other modalities. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] In addition to dynamic leaf motion as in dynamic-MLC IMRT, RapidArc TM (Varian Medical Systems, Palo Alto, CA) utilizes gantry rotation as well as variations in gantry speed and dose rate. Many studies have advocated that the inherent complexities of this technique require similar, but additional, commissioning and quality assurance than that of conventional IMRT.…”

Dosimetric comparison of volumetric modulated arc therapy and intensity-modulated radiation therapy for pancreatic malignancies

“…To date, there have been a few dosimetric studies presented as poster sessions by groups evaluating VMAT use in limited numbers of pancreatic cancer cases, but there has yet to be any formally published data in a peer-reviewed journal reporting a strictly regimented comparison of VMAT and IMRT for pancreatic cancer. 15,16 The abstract by Eppinga et al reports improved confidence interval and significantly reduced monitor units, right kidney V 15 dose, left kidney V 15 dose, liver mean dose, stomach mean dose, and small bowel mean dose. 15 The abstract by Verbakel et al did not specifically differentiate pancreatic tumor dosimetric parameters from the other included sites.…”

“…15 The abstract by Verbakel et al did not specifically differentiate pancreatic tumor dosimetric parameters from the other included sites. 16 This study includes a direct comparison of VMAT and IMRT plans generated for patients previously treated for pancreatic cancer. Data presented include dosimetric endpoints for OAR, PTV coverage characteristics, and delivery parameters for both VMAT and IMRT plans.…”